SBI Healthcare Opportunities Fund Direct Growth

Fund Overview

Fund Size

₹4,566 Cr

Expense Ratio

0.91%

ISIN

INF200K01UP2

Minimum SIP

₹1,000

Exit Load

No Charges

Inception Date

01 Jan 2013

About this fund

SBI Healthcare Opportunities Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by SBI Mutual Fund. This fund has been in existence for 13 years, 5 months and 18 days, having been launched on 01-Jan-13.
As of 17-Jun-26, it has a Net Asset Value (NAV) of ₹541.78, Assets Under Management (AUM) of 4565.95 Crores, and an expense ratio of 0.91%.

SBI Healthcare Opportunities Fund Direct Growth has given a CAGR return of 17.74% since inception.
The fund's asset allocation comprises around 97.49% in equities, 0.06% in debts, and 2.45% in cash & cash equivalents.
You can start investing in SBI Healthcare Opportunities Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+12.19%

+10.36% (Cat Avg.)

3 Years

+24.79%

+22.46% (Cat Avg.)

5 Years

+17.07%

+13.64% (Cat Avg.)

10 Years

+14.68%

+14.85% (Cat Avg.)

Since Inception

+17.74%

— (Cat Avg.)

Portfolio Summaryas of 31st May 2026

Equity	₹4,451.25 Cr	97.49%
Debt	₹2.92 Cr	0.06%
Others	₹111.78 Cr	2.45%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹503.78 Cr	11.03%
Divi's Laboratories Ltd	Equity	₹300.02 Cr	6.57%
Acutaas Chemicals Ltd	Equity	₹281.93 Cr	6.17%
Apollo Hospitals Enterprise Ltd	Equity	₹245.3 Cr	5.37%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹217.15 Cr	4.76%
Aurobindo Pharma Ltd	Equity	₹178.3 Cr	3.90%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹174.8 Cr	3.83%
Laurus Labs Ltd	Equity	₹163.44 Cr	3.58%
Biocon Ltd	Equity	₹160.74 Cr	3.52%
Torrent Pharmaceuticals Ltd	Equity	₹158.79 Cr	3.48%
Fortis Healthcare Ltd	Equity	₹139.27 Cr	3.05%
Anthem Biosciences Ltd	Equity	₹136.96 Cr	3.00%
Gland Pharma Ltd	Equity	₹135 Cr	2.96%
Mankind Pharma Ltd	Equity	₹133.03 Cr	2.91%
Aether Industries Ltd	Equity	₹120.78 Cr	2.65%
Jupiter Life Line Hospitals Ltd	Equity	₹119.44 Cr	2.62%
Sai Life Sciences Ltd	Equity	₹116 Cr	2.54%
Treps	Cash - Repurchase Agreement	₹113.18 Cr	2.48%
Sudeep Pharma Ltd	Equity	₹100.93 Cr	2.21%
Lonza Group Ltd ADR	Equity	₹97.66 Cr	2.14%
Alkem Laboratories Ltd	Equity	₹96.22 Cr	2.11%
Krishna Institute of Medical Sciences Ltd	Equity	₹91.06 Cr	1.99%
Lupin Ltd	Equity	₹90.71 Cr	1.99%
Ajanta Pharma Ltd	Equity	₹87.87 Cr	1.92%
Poly Medicure Ltd	Equity	₹86.38 Cr	1.89%
Cipla Ltd	Equity	₹84.06 Cr	1.84%
Cohance Lifesciences Ltd	Equity	₹77.67 Cr	1.70%
Concord Biotech Ltd	Equity	₹75.69 Cr	1.66%
Abbott India Ltd	Equity	₹67.14 Cr	1.47%
Global Health Ltd	Equity	₹66.58 Cr	1.46%
Nephrocare Health Services Ltd	Equity	₹47.9 Cr	1.05%
Rainbow Childrens Medicare Ltd	Equity	₹41.41 Cr	0.91%
Dr. Lal PathLabs Ltd	Equity	₹38.58 Cr	0.84%
Gufic Biosciences Ltd	Equity	₹16.69 Cr	0.37%
Day Tbill	Bond - Gov't/Treasury	₹2.92 Cr	0.06%
Net Receivable / Payable	Cash - Collateral	₹-1.4 Cr	0.03%

Allocation By Market Cap (Equity)

Allocation By Credit Quality (Debt)

AAA

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹4,048.55 Cr	88.67%
Basic Materials	₹402.71 Cr	8.82%

Risk & Performance Ratios

Fund Managers

Tanmaya Desai

Since June 2011

Additional Scheme Detailsas of 31st May 2026

ISIN

INF200K01UP2

Expense Ratio

0.91%

Exit Load

No Charges

Fund Size

₹4,566 Cr

Age

13 years 5 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Groww BSE Hospitals ETF Very High Risk	0.5%	-	₹50.02 Cr	-
Mirae Asset Nifty 500 Healthcare ETF Very High Risk	0.1%	-	₹12.06 Cr	-
Bandhan Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹310.92 Cr	-
Bandhan Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹310.92 Cr	-
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.6%	1.0%	₹544.17 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.1%	1.0%	₹544.17 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹332.52 Cr	11.0%
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹332.52 Cr	12.9%
PGIM India Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹95.49 Cr	15.7%
PGIM India Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹95.49 Cr	13.6%
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.0%	0.0%	₹664.02 Cr	16.1%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹664.02 Cr	18.1%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹14.94 Cr	11.2%
Kotak Healthcare Fund Direct Growth Very High Risk	0.9%	0.0%	₹560.17 Cr	19.5%
Kotak Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹560.17 Cr	17.5%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹2362.44 Cr	20.3%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹2362.44 Cr	21.7%
Nippon India Pharma Fund Direct Growth Very High Risk	0.8%	1.0%	₹8635.75 Cr	7.5%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.6%	1.0%	₹6453.52 Cr	7.5%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	0.9%	1.0%	₹6453.52 Cr	8.4%
DSP Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹3309.17 Cr	8.9%
DSP Healthcare Fund Regular Growth Very High Risk	1.7%	0.0%	₹3309.17 Cr	7.5%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹88.96 Cr	9.7%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹88.96 Cr	8.3%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹372.50 Cr	9.3%
quant Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹372.50 Cr	7.5%
UTI Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹1216.85 Cr	13.2%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹4565.95 Cr	12.2%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	1.8%	0.0%	₹1386.99 Cr	7.1%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹1386.99 Cr	8.7%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹202.94 Cr	11.3%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹4565.95 Cr	11.1%
Nippon India Pharma Fund Regular Growth Very High Risk	1.5%	1.0%	₹8635.75 Cr	6.6%
UTI Healthcare Fund Regular Growth Very High Risk	2.2%	1.0%	₹1216.85 Cr	12.1%
Axis NIFTY Healthcare ETF Very High Risk	0.4%	-	₹22.75 Cr	11.0%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹1570.17 Cr	13.2%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.7%	1.0%	₹3090.51 Cr	12.7%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹3090.51 Cr	14.4%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹237.99 Cr	4.1%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹237.99 Cr	6.0%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹76.47 Cr	11.2%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹950.31 Cr	12.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹950.31 Cr	13.9%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.3%	-	₹39.76 Cr	10.4%

About the AMC

SBI Mutual Fund

022 - 61793000

https://www.sbimf.com/

Total AUM

₹12,86,586 Cr

Address

C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051

Other Funds by SBI Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
SBI CRISIL-IBX 10:90 Gilt + SDL Index - Dec 2029 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹27.39 Cr	-
SBI Nifty G-sec Jul 2031 Index Fund Direct Growth Moderate Risk	0.2%	0.0%	₹15.73 Cr	-
SBI CRISIL-IBX Financial Services 9-12 Months Debt Index Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹230.49 Cr	-
SBI CRISIL-IBX Financial Services 3-6 Months Debt Index Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹211.28 Cr	-
SBI Quality Fund Direct Growth Very High Risk	0.8%	1.0%	₹2361.00 Cr	-
Magnum Hybrid Long Short Fund Direct Growth Low to Moderate Risk	0.5%	0.0%	₹3454.26 Cr	-
SBI Dynamic Asset Allocation Active FoF Direct Growth High Risk	0.4%	1.0%	₹2311.42 Cr	-
SBI Nifty100 Low Volatility 30 Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹59.97 Cr	-
SBI Nifty200 Momentum 30 Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹125.23 Cr	-
SBI NIFTY 200 Quality 30 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹316.26 Cr	-1.1%
SBI Income Plus Arbitrage Active FOF Direct Growth Moderate Risk	0.1%	0.0%	₹1801.38 Cr	5.4%
SBI BSE PSU Bank Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹321.88 Cr	26.8%
SBI Nifty IT Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹92.70 Cr	-25.7%
SBI Nifty Bank Index Fund Direct Growth Very High Risk	0.2%	0.0%	₹167.84 Cr	4.5%
SBI Quant Fund Direct Growth Very High Risk	0.9%	0.0%	₹3055.17 Cr	2.2%
SBI Nifty India Consumption Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹263.54 Cr	1.8%
SBI Nifty 500 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹759.92 Cr	1.8%
SBI Innovative Opportunities Fund Direct Growth Very High Risk	0.9%	1.0%	₹4935.25 Cr	0.6%
SBI Silver ETF Fund of Fund Direct Growth Very High Risk	0.3%	1.0%	₹4190.30 Cr	117.1%
SBI Automotive Opportunities Fund Direct Growth Very High Risk	0.9%	1.0%	₹5177.78 Cr	27.1%
SBI Energy Opportunities Fund Direct Growth Very High Risk	0.8%	1.0%	₹8906.34 Cr	10.5%
SBI Fixed Maturity Plan Series 92 91 Days Direct Growth Moderate Risk	-	0.0%	-	-
SBI Nifty50 Equal Weight Index Fund Direct Growth Very High Risk	0.5%	0.0%	₹1048.04 Cr	5.9%
SBI Fixed Maturity Plan (FMP) - Series 91 (90 Days) Direct Growth Moderately High risk	-	0.0%	-	-
SBI Debt Fund Series C 24 Direct Growth Low to Moderate Risk	-	0.0%	-	4.4%
SBI Fixed Maturity Plan (FMP) - Series 47 (1434 Days) Direct Growth Low Risk	-	0.0%	₹144.26 Cr	7.0%
SBI Fixed Maturity Plan Series 41 1498 Days Direct Growth Low Risk	-	0.0%	₹915.41 Cr	7.0%
SBI Long Term Advantage Fund Series II Direct Growth Very High Risk	-	0.0%	₹34.17 Cr	6.8%
SBI Debt Fund Series C 25 Direct Growth Low to Moderate Risk	-	0.0%	-	5.1%
SBI Fixed Maturity Plan (FMP) - Series 60 (1878 Days) Direct Growth Low to Moderate Risk	-	0.0%	₹264.17 Cr	5.8%
SBI Fixed Maturity Plan (FMP) - Series 74 1243 Days Direct Growth Low to Moderate Risk	-	-	₹154.11 Cr	5.7%
SBI Fixed Maturity Plan Series 78 1170 Days Direct Growth Low to Moderate Risk	-	0.0%	₹122.06 Cr	5.9%
SBI Fixed Maturity Plan Series 66 1361 Days Direct Growth Moderate Risk	-	0.0%	₹662.46 Cr	6.0%
SBI Fixed Maturity Plan Series 57 1835 Days Direct Growth Low Risk	-	-	₹274.23 Cr	5.8%
SBI Fixed Maturity Plan (FMP) - Series 80 366 Days Direct Growth Moderate Risk	-	0.0%	-	7.6%
SBI Fixed Maturity Plan Series 1 3668 Days Direct Growth Moderate Risk	-	0.0%	₹51.07 Cr	5.1%
SBI Fixed Maturity Plan Series 81 1157 Days Direct Growth Low Risk	-	0.0%	₹399.49 Cr	5.8%
SBI Fixed Maturity Plan (FMP) - Series 49 (1823 Days) Direct Growth Low Risk	-	0.0%	₹419.19 Cr	5.7%
SBI Fixed Maturity Plan (FMP) - Series 75 (366 Days) Direct Growth Moderate Risk	-	-	-	7.5%
SBI Fixed Maturity Plan Series 46 1850 Days Direct Growth Low Risk	-	0.0%	₹140.37 Cr	5.5%
SBI Fixed Maturity Plan Series 53 1839 Days Direct Growth Low Risk	-	-	₹330.67 Cr	5.8%
SBI Long Term Advantage Fund Series I Direct Growth Low Risk	-	0.0%	₹49.50 Cr	17.1%
SBI Fixed Maturity Plan Series 79 1130 Days Direct Growth Low Risk	-	0.0%	₹79.97 Cr	6.1%
SBI Long Term Advantage Fund Series VI Direct Growth Very High Risk	-	0.0%	₹250.68 Cr	1.1%
SBI Fixed Maturity Plan Series 76 1221 Days Direct Growth Low Risk	-	-	₹161.44 Cr	5.6%
SBI Tax Advantage Fund Series III Direct Growth Very High Risk	-	0.0%	₹33.26 Cr	32.0%
SBI Fixed Maturity Plan Series 73 1226 Days Direct Growth Low Risk	-	-	₹196.01 Cr	6.1%
SBI Fixed Maturity Plan Series 44 1855 Days Direct Growth Low Risk	-	0.0%	₹410.59 Cr	5.5%
SBI Fixed Maturity Plan Series 65 367 Days Direct Growth Low to Moderate Risk	-	0.0%	-	-
SBI Fixed Maturity Plan (FMP) - Series 58 (1842 Days) Direct Growth Low to Moderate Risk	-	-	₹268.76 Cr	5.8%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Dezerv

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of SBI Healthcare Opportunities Fund Direct Growth?

The NAV of SBI Healthcare Opportunities Fund Direct Growth, as of 17-Jun-2026, is ₹541.78.

What are the returns of SBI Healthcare Opportunities Fund Direct Growth?

The fund has generated 12.19% over the last 1 year and 24.79% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of SBI Healthcare Opportunities Fund Direct Growth?

The fund's allocation of assets is distributed as 97.49% in equities, 0.06% in bonds, and 2.45% in cash and cash equivalents.

Who manages the SBI Healthcare Opportunities Fund Direct Growth?

The fund managers responsible for SBI Healthcare Opportunities Fund Direct Growth are:-

Tanmaya Desai

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2026 Dezerv. All Rights Reserved

Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

SBI Healthcare Opportunities Fund Direct Growth

Fund Overview